365 related articles for article (PubMed ID: 17543077)
1. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
2. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
5. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K
J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.
Skov BG; Fischer BM; Pappot H
Lung Cancer; 2008 Jan; 59(1):88-94. PubMed ID: 17905466
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
8. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
Bozkurt KK; Kapucuoğlu N
Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
[TBL] [Abstract][Full Text] [Related]
10. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
[TBL] [Abstract][Full Text] [Related]
11. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
Jolly S; Kestin LL; Goldstein NS; Vicini FA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta.
Papadaki I; Mylona E; Giannopoulou I; Markaki S; Keramopoulos A; Nakopoulou L
Histopathology; 2005 Jan; 46(1):37-42. PubMed ID: 15656884
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein90 in lobular neoplasia of the breast.
Zagouri F; Nonni A; Sergentanis TN; Papadimitriou CA; Michalopoulos NV; Lazaris AC; Patsouris E; Zografos GC
BMC Cancer; 2008 Oct; 8():312. PubMed ID: 18957107
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
[TBL] [Abstract][Full Text] [Related]
15. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors.
Jarzabek K; Koda M; Kozlowski L; Mittre H; Sulkowski S; Kottler ML; Wolczynski S
Eur J Cancer; 2005 Dec; 41(18):2924-34. PubMed ID: 16289616
[TBL] [Abstract][Full Text] [Related]
16. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies.
Gao F; Carter G; Tseng G; Chivukula M
Am J Clin Pathol; 2010 May; 133(5):767-71. PubMed ID: 20395524
[TBL] [Abstract][Full Text] [Related]
17. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
18. [A follow-up study about 52 cases of atypical lobular hyperplasia and lobular carcinoma in situ of the breast].
Li HY; Ren GS; Arnould N; Brettes JP
Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(13):874-6. PubMed ID: 17953828
[TBL] [Abstract][Full Text] [Related]
19. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
20. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
